Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Parliament Explains ‘Vanishing’ Study On Balancing Access & Innovation In EU

Executive Summary

Changes are being made to a prematurely published study that proposes an EU drug procurement authority, a centralized pharmaceutical fund and a European pharmaceutical R&D infrastructure to match public health needs with R&D investment.

You may also be interested in...

Controversial EU Study On Pharma Innovation & Access Sees The Light Of Day

Members of the European Parliament committee charged with leading the negotiations on the review of the EU pharmaceutical legislation have been presented with a study backing cuts in data protection and wider joint procurement of medicines outside emergency situations.

EU Parliament Report Calls For Nine-Year Data Protection Period

The rapporteur for the draft directive that is part of the proposed EU legislative revision package says the pharmaceutical industry needs certainty and long-term predictability regarding the expected level of regulatory data protection. But her proposal to increase the RDP period is not shared by the rapporteur for the draft regulation.

Bigger Trials, More RWE Needed for Future Crisis Response, Say EU Regulators

A report from the EU medicines regulatory network looks at what was done well in the response to the COVID-19 pandemic, and what needs to be improved if we are to be better prepared next time. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts